New scientific presentations highlight breakthrough innovations in skincare and self-care solutions.
Dubai, UAE: Kenvue, the world’s largest pure-play consumer health company by revenue, presented research at the 9th International Congress of Medical Excellence in Dermatology and Aesthetic Medicine (MEIDAM). The company participated as a Platinum Sponsor, demonstrating its commitment to advancing skincare science and expanding access to innovative self-care solutions.
Kenvue participated at MEIDAM this year with research across its flagship brands highlighting the power of everyday care and the latest innovations from its iconic brands – Regaine®, Aveeno® and Neutrogena® – reaffirming its commitment to delivering innovative, science-backed products.
Rodney Smith, GCC Managing Director for Kenvue: “Our participation at MEIDAM goes beyond showcasing product innovation; it underscores our commitment to collaborating with top healthcare professionals to drive dermatologist-led science forward. By partnering within the industry, we’re fusing science and innovation to educate consumers and make these advanced solutions accessible globally. Our collaborations are building stronger connections with the healthcare professional community, retailers, and consumers alike, all working together toward a future where science-backed care is within reach for everyone.”
The team featured significant scientific lectures as Aveeno® presented research on Atopic Dermatitis, showcasing how the Triple Oat Complex can bring life-changing relief with oat extract, and oat oil. The research built on the brand’s 75-year legacy in skin science and is supported by more than 30 clinical studies, involving over 3,000 participants.
Neutrogena®, the #3 global dermo cosmetics brand[1], made its MEIDAM debut and presented findings showcasing its leadership in the science of retinol and hyaluronic acid for skin rejuvenation through an engaging workshop session. Furthermore, at the event, Regaine® presented scientific lectures on debunking myths on minoxidil in the treatment of androgenetic alopecia (a common type of hair loss in men and women).
Kenvue’s presence at MEIDAM continued through November 17, with research presentations and professional education sessions. Leading dermatologists and other skin specialists visited the Kenvue booth to learn more about the company’s latest innovations and scientific developments.
